![]() | |
Names | |
---|---|
Preferred IUPAC name
4-(2-{[7-Amino-2-(furan-2-yl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino}ethyl)phenol | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.216.533 |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C16H15N7O2 | |
Molar mass | 337.343 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
ZM-241,385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.[1]
In animal models, ZM-241,385 has been shown to protect against beta amyloid neurotoxicity and therefore may be useful as a treatment for Alzheimer's disease.[2] ZM-241,385 has also been shown to enhance L-DOPA derived dopamine release and therefore may be useful in the treatment of Parkinson's disease.[3]
References
[edit]- ^ Palmer TM, Poucher SM, Jacobson KA, Stiles GL (December 1995). "125I-4-(2-(7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5) triazin-5-yl-amino)ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor". Molecular Pharmacology. 48 (6): 970–4. PMC 3479638. PMID 8848012.
- ^ Dall'Igna OP, Porciúncula LO, Souza DO, Cunha RA, Lara DR, Dall'lgna OP (April 2003). "Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity". British Journal of Pharmacology. 138 (7): 1207–9. doi:10.1038/sj.bjp.0705185. PMC 1573785. PMID 12711619.
- ^ Gołembiowska K, Dziubina A (September 2004). "Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats". Neuropharmacology. 47 (3): 414–26. doi:10.1016/j.neuropharm.2004.04.018. PMID 15275831. S2CID 13484028.
External links
[edit]ZM+241385 at the U.S. National Library of Medicine Medical Subject Headings (MeSH)